> Strategies for Monoclonal Antibody Therapy 2004 > Therapeutic applications, products in clinical trials and future outlook > 1st & 2nd July, Hilton Kensington Hotel, London > > > * Monoclonal antibody therapies are becoming an important weapon in the > fight against cancer, autoimmune diseases, transplant rejection > and many other diseases/conditions. > > Monoclonal Antibodies Sales are forecast to grow by over 400% by 2009. > > * This conference will address all of the relevant issues in this growing > sector; including methods to lower production costs and realise greater > profits. > > Themes will include: > * Handling cost issues of MAb treatment > * Overcoming problems of antibody production > * The future of MAb> '> s: transgenic proteins > * Case studies: analysis of major drugs in the market > * Case studies: potential of products in clinical trials > * Case studies: innovative delivery systems > > Industry Leading speakers confirmed at this event: > * Dr. Andrea Feyereislova, Clinical Science Leader for Herceptin, Roche > * Bob Ward, Senior Director, Commercial Development Biologics and Small > Molecules, Schering-Plough > * Rene Imwinkelreid, Head of Lonza Biologics, Lonza Biologics > * Dr. Joachim Kalmus, Clinical Development Oncology, Schering > * Ralph Minter, Senior Research Scientist, Cambridge Antibody Technology > * Dr. David Humphreys, Celltech R&D, Celltech > * Stephen Squinto, Executive VP and Head of Research, Alexion > Pharmaceuticals > * Dr. Zhenping Zhu, Assistant Vice President Head, Antibody Technology, > ImClone Systems > * Dr. Herren Wu, Senior Director, Antibody Discovery & Protein > Engineering, MedImmune > * Dr. Lorin Roskos, Senior Director, Pharmacokinetics and Toxicology, > Abgenix > > Who Should Attend? (job titles) > * Senior Director, Antibody Discovery > * Senior Scientist, Protein Technology Biosciences > * Director, Antibody Technologies / Engineering > * Director, Protein Engineering & Structure > * Senior Director, Immunology > * Head, Expression and Cell Science > * Biologics Manufacturing Development Manager > * Chief Technical Officer > * Director, Preclinical R&D > * Director, Product Development > * Vice President, Research and Development > - plus all senior representatives involved in monoclonal antibody > production/research. > > Places at this event are limited, please call or email me now to secure your > place > > - PRICING - > Attend the: > ** Conf. + pre conf. workshop GBP 1600.00 Plus VAT > ** Conference only Fee: GBP1299.00 Plus VAT > ** Pre conference workshop only Fee: GBP 650.00 Plus VAT > > - BOOKINGS - > Booking is easy, simply contact Lorraine Lescure on: > Telephone: +44 (0)20 8767 6711 > Fax: +44 (0)20 8767 5001 > Email: mailto:[EMAIL PROTECTED] > Terms and conditions apply - see below. > > I look forward to hearing from you soon. > > Regards, > Lorraine Lescure > Account Manager > Visiongain b2b Conferences > Tel: +44 (0) 20 8767 6711 > http://www.b2b-conferences.com > mailto:[EMAIL PROTECTED] > > > > > Sponsorship Opportunities > This event will provide unrivalled opportunities to promote your brand to an > audience of senior level delegates. > Options include: > * Full Conference Sponsorship > * Exhibition Stand/Booth > * Promotional Inserts > * Delegate Bag Sponsor > * Cocktail Reception Sponsor > Whatever your budget, whatever your requirements we can find you a way to > place your brand at Monoclonal Antibody Therapy 2004.- reply to [EMAIL > PROTECTED] for more info. > > > > - Agenda - > > Pre-Conference Interactive Workshop > Monoclonal Antibodies: > Pointers for Pre-Clinical Studies > Wednesday 30th June 2004 > Workshop Leader: Hanne Kristensen, Diatec > > 09:40 Coffee and Registration > > 10:00 Introduction from workshop leader > *> Overview of different technologies used by Diatec for > production > *> Practical examples > *> Purification and downstream processing> > *> Quality control > *> Benefits of using a small, ISO 9001 certified company for > research > *> speed of production > *> flexibility > *> process development knowledge > > About the company > Diatec.com is a Norwegian biotechnology company producing and > selling monoclonal antibodies for world-wide distribution. > > Strategies for Monoclonal Antibody Therapy 2004 > Day One Thursday 1st July 2004 > > Conference Chairman > Bob Ward, Senior Director ,Commercial Development, Biologics and > Small Molecules, Schering-Plough > > 9:00 Registration and coffee > > 9:30 Opening remarks from the Chair > > INTRODUCTION > > 9:40 How to Overcome Obstacles for Successful MAb Treatment > *> Selecting the best MAb for a given target: a rational approach to > MAb design goals > *> Justifying first-in-human studies: preclinical efficacy, safety, and > pharmacokinetics > *> Bad target or wrong dose? Selection of the optimum clinical dose > *> Managing the risk of immunogenicity > Dr. Lorin Roskos > Senior Director, Pharmacokinetics and Toxicology > Abgenix > > 10:20 Contract Manufacturers: A Strategic Asset for your Company > *> Contract manufacturers: filling the needs of biotech companies > *> How has this niche industry grown? > *> Reasons for success- full process development and regulatory > support > *> Stages: vector construction, cell line development to full scale > manufacture > Rene Imwinkelreid > Head of Lonza Biologics > Lonza Biologics > > 11:00 Morning Coffee > > ANTIBODY PRODUCTION > > 11:20 Process Development Requirements for Antibody > Therapeutics > *> Approach for antibody therapeutic products > *> Generic process applications- cycle time reduction? > *> Overcoming problems posed by production capacity > *> Improving purification steps in the production process > *> Regulatory considerations > Cristina Glad > Executive Vice President > BioInvent > > 12:00 Strategies to Overcoming Immune Reactivity > *> Problems of immune response and impact on therapeutic > antibodies > *> Strategies for chimeric and humanised antibodies > *> Molecular imprinted polymer (MIP) for engineering synthetic > antibodies > *> Antibody engineering with target-activated enzymes > Dr. Dee Athwal > Senior Principal Scientist > Celltech > > 12:40 Lunch > > 14:00 CAT-354: An IL13 Neutralising Antibody Optimised by > Ribosome Display > *> Ribosome display - a versatile technology for protein engineering > *> Optimisation strategies - the combination of targeted and > evolutionary approaches > *> The results of antibody engineering - production of antibody CAT-354 > *> The next stages of pre-clinical development for CAT-354 > Ralph Minter > Senior Research Scientist > Cambridge Antibody Technology > > 14:40 CASE STUDY: Simplifying the Purification of Periplasmic Fab', > the Creation and use of New E. coli Strains > *> What are the benefits of Fab' production in the E. coli periplasm? > *> Study of host protein mutation and co-purification with Fab > *> The creation and use of new E. coli strains: chromosomal gene > replacement > *> What are the benefits of simplified purification regimes? > *> The future: supplying large market indications with high quality > drug > Dr. David Humphreys > Celltech R&D > Celltech > > 15:20 Afternoon Tea > > THERAPEUTIC APPLICATIONS > > Over two-thirds of monoclonal antibody products are for transplant rejection, > cancer, autoimmune diseases and infectious diseases > > 15:40 CASE STUDY: The Success of Remicade in treating > Inflammatory Conditions > *> The role of inflammatory cytokines in patients with crohn's disease > - the cytokine tumour necrosis factor-alpha (TNF-alpha) > *> How does this chimeric human: mouse antibody neutralise TNF-alpha? > *> Role of remicade as an anti-TNF-blocking therapy for rheumatoid > arthritis > *> Clinical efficacy of infliximab > - short and long term benefits > - treatment of refractory Behcet syndrome > *> The success of remicade- marketing approvals and global sales> > Bob Ward > Senior Director ,Commercial Development > Biologics and Small Molecules > Schering-Plough > > 16:20 CASE STUDY: Zevalin, a Novel Treatment Regime > Zevalin is the first product with a monoclonal antibody that is > combined with a radioactive chemical for the treatment of non-Hodgkin > lymphoma > *> Two part administration of Zevalin: screening and treatment > *> Results from safety and efficacy studies > *> Toxicity of treatment- limiting use > *> How effective is it in patients who are refractory to antibody > treatment? > Dr. Joachim Kalmus > Clinical Development Oncology > Schering > > 17:00 Questions and Discussion > > 17:10 Summation of day one from conference chair > > 17:20 Close of Day One > > Strategies for Monoclonal Antibody Therapy 2004 > Day Two Friday 2nd July 2004 > > 9:00 Registration and Coffee > > 9:30 Opening remarks from the chair > > 9:40 A Potent New Generation Anti-Tumour MUC1 Antibody > *> How the antibody recognises the novel tumour-specific epitope TA-MUC1 > *> Results after 3 days of injection in the tumour of skin xenografted > nude mice > *> Tumour efficacy studies in mice > *> Advantages over Pemtumomab: higher affinity, higher tumour > specificity, lower binding to serum MUC1, and lower binding to > PBMC > *> Primary indication: GI cancers; secondary indications: other > carcinomas, e.g. breast, ovarian, kidney cancer > Dr. Steffen Goletz > Chief Scientific Office > Leiter Forschung & Entwicklung > NEMOD Biotherapeutics GmbH & Co.KG > > 10:20 CASE STUDY: Herceptin, First FDA Approved Treatment for > Breast Cancer > *> Anti-cancer benefits of Herceptin > - binding to HER2 and blocking growth factors > - killing of cancer cells by the stimulation of the immune system > *> Phase III trials: Herceptin in women with HER2 positive early stage > breast cancer as adjuvant therapy > *> Results of safety and efficacy studies > Dr. Andrea Feyereislova > Clinical Science Leader for Herceptin > Roche > > 11:00 Morning Coffee > > 11:20 CASE STUDY: Synagis, only Monoclonal Antibody Approved > to prevent Respiratory Syncytial Virus (RSV) > *> First MAb successfully developed to combat infectious disease: > mode of action > *> Safety and efficacy studies > *> Advantages over previous treatments > *> Development of Numax > - second generation of Synagis > Dr. Herren Wu > Senior Director > Antibody Discovery & Protein Engineering > MedImmune > > R&D: PRODUCTS IN CLINICAL TRIALS > > 12:00 CASE STUDY: The Potential of Erbitux > *> Target: epidermal growth factor receptor > *> Results of clinical studies > - biological activity in a number of tumours > *> Results from monotherapy > - patients with colorectal cancer > - metastatic colorectal cancer > *> Efficacy and safety of Erbitux > - patients with advanced solid tumours > Dr. Zhenping Zhu > Assistant Vice President Head > Antibody Technology > ImClone Systems > > 12:40 Lunch > > 14:00 CASE STUDY: Eculizumab, Humanised MAb in a New Class of > Drugs > *> Complement-5 inhibitors: activation methods > *> Phase I/II results for rheumatoid arthritis, nephritis, systemic lupus, > psoriasis, dermatomyositis and pemphigoid > *> Predicted worldwide sales for different indications > *> Orphan Drug Status: treating paroxysmal nocturnal hemoglobinuria > Stephen Squinto > Executive VP and Head of Research > Alexion Pharmaceuticals > > FUTURE OUTLOOK: TRANSGENIC PROTEINS > > 14:40 Transgenic Plants: A New Model to meet Production Needs > *> Potential of this segment > - is it really a viable alternative? > *> Large scale genetically engineered proteins an option for less > complex proteins? > *> Overcoming technical issues > *> Challenges > Dominique Mison > Bio-industrial Director > Meristem Therapeutics > > 15:20 Afternoon Tea > > INNOVATIVE DELIVERY SYSTEMS > > 15:40 CASE STUDY: Crystalline MAb Formulations for > Subcutaneous Delivery > *> MAb's: limitations of current administration and use> > *> Altus Crystalomics TM protein crystallisation technology for > subcutaneous delivery > *> Pharmacokinetic profile and pharmacodynamic efficacy in vivo > *> Advantages of delivery method: higher concentrations, low dose > volume, low viscosity, high stability > *> New opportunities for biopharmaceutical applications > Dr. Sujit Basu > Group Leader > Parenteral Formulation and Delivery > Altus Biologics > > 16:20 Questions and Discussion > > 16:40 Chairman Summation > > 16:50 Close of Conference > > > > > Visiongain/B2B Conferences produce a range of timely business information > material, if you wish to receive information of new products, simply reply to > this email with ' New Products info' in the subject box > > > > > > > > > > > Terms & Conditions > NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for > an invoice to be raised will be treated as an official booking and will be > subject to the cancellation policy as outlined below. > Cancellations/substitutions and name changes: All bookings carry a 50% > liability after the booking has been made, by post fax, email or web. There > will be no refunds for cancellations received on or after one month before > the start of the conference (e.g. cancellation on or after 20th January for a > conference starting on 20th February). If you decide to cancel after this > date the full invoice remains payable. Conference notes, which are available > on the day, will be sent to you. Unfortunately we are not able to transfer > places between conferences and executive briefings. However if you are unable > to attend the event you may make a substitution/name change at any time as > long as we are informed in writing by e-mail, fax or post. Name changes and > substitutions must be from the same company and are not transferable between > companies or countries. > > Indemnity: visiongain Ltd reserve the right to change the > conference/executive briefing content, timing, speakers or venue without > notice. The event may be postponed or cancelled due to acts of terrorism, > war, extreme weather conditions, industrial action, acts of God or any event > beyond the control of visiongain Ltd. If such a situation arises we will > endeavour to reschedule the event. However, visiongain Ltd cannot be held > responsible for any cost, damage or expenses, which may be incurred by the > customer as a consequence of the event being postponed or cancelled. We > therefore strongly advise all customers to take out insurance to cover the > cost of the registration, travel and expenses. > To unsubscribe please reply with unsubscribe in the subject line. > Data protection: Visiongain Ltd gathers and manages data in accordance with > the Data Protection Act 1998. Information contained about you may be used to > update you on visiongain Ltd products and services via post, telephone, fax > or email, unless you state otherwise. If you wish your details to be amended, > please send your request to the Database Manager, visiongain Ltd, 40 Tooting > High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in > the subject line. Please allow approximately 7 days for your removal or > update request, you may receive additional pieces of communication from > visiongain Ltd during the transitional period, whilst the changes come into > effect. > > > > > > > > > > > > > > #####################################################################################
This email has been scanned by MailMarshal, an email content filter. #####################################################################################
